Promise and challenges for psilocybin and MDMA use in treatment
What lies ahead before FDA approval
#150 – Senator Bill Frist, M.D.: A modern Renaissance man’s journey through science, politics, and business
“Public health has been the stepchild of health and welfare and healing. That is inverted now, and people appreciate it, but are we going to actually deliver on it? Not just next year, and not just put more funding in it, but really do it over a period of time?” —Bill Frist
#148 – Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the Interventions Testing Program
“I don’t really care what causes aging. What I care about is: What is the process that can postpone all the different aspects of aging?” — Rich Miller
#132 – AMA #16: Exploring hot and cold therapy
“All of the work that went into this analysis earlier in the year, it really changed my tune. And I think I’m now at the point where I kind of want to have a sauna, frankly, in the tool kit for longevity.” — Peter Attia
#103 – Looking back on the first 99 episodes: Strong Convictions, Loosely Held
“I reserve metformin prescriptions for patients who obviously are in need of it from the standpoint of glucose and insulin regulation, but I don’t view it really as a pro longevity agent yet.” — Peter Attia
#81 – Debra Kimless, M.D. & Steve Goldner, J.D.: Cannabis – the latest science on CBD & THC
“Cannabis is a gateway more towards health than to other drugs.” —Steve Goldner
Qualy #61 – Rapamycin in cancer treatment
Today’s episode of The Qualys is from podcast #10 – Matt Kaeberlein, Ph.D.: rapamycin and dogs — man’s best friends?…
Qualy #52 – Insights about berberine
Today’s episode of The Qualys is from podcast #26 – AMA #3: supplements, women’s health, patient care, and more.
Qualy #46 – Rapamycin’s effects on cancer, cardiovascular disease, and neurodegeneration
Today’s episode of The Qualys is from podcast #09 – David Sabatini, M.D., Ph.D.: rapamycin and the discovery of mTOR…
#75 – David Light: Zantac recall due to cancer concerns – what you need to know
“We have to come to grasp the reality that there are problems in the medication system in generics, potentially even brand, and all sorts of holes that exist in how the system is now for medications. We want to be a part of that solution and work together to ensure that every patient is getting a high quality medication.” — David Light